Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
Q3 2024 vs. Q2 2024
How the institutions holding Jasper Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 69 | 1 | 81 | +13 |
| Shares | 14.6M | 693.0K | 14.7M | +812.9K (+5.9%) |
| Value | $329.8M | $15.7M | $274.8M | −$39.3M (−12.5%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (25)
Institutions that held Jasper Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (12)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Avidity Partners Management LP | 782,000 | $17.8M |
| Octagon Capital Advisors LP | 287,500 | $6.53M |
| StemPoint Capital LP | 143,775 | $3.26M |
| Silverarc Capital Management, LLC | 109,892 | $2.49M |
| Cantor Fitzgerald, L. P. | 61,603 | $1.40M |
| Walleye Capital LLC | 52,669 | $1.20M |
| Millennium Management LLC | 22,990 | $521.9K |
| EAM Investors, LLC | 21,525 | $488.6K |
| Bamco Inc | 20,000 | $454.0K |
| Invesco Ltd. | 19,121 | $434.0K |
| Alpine Global Management, LLC | 10,719 | $243.3K |
| Quarry LP | 1,000 | $22.7K |
Not filed for Q3 2024 yet (1)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 692,980 | $15.7M |